...
首页> 外文期刊>The American Journal of Cardiology >On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study)
【24h】

On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study)

机译:急性冠状动脉综合征住院后他汀类药物的抵抗素,瘦素和冠状动脉事件复发的风险(来自普伐他汀或阿托伐他汀的评估和心肌梗死的感染治疗-血栓溶解22研究)

获取原文
获取原文并翻译 | 示例
           

摘要

Resistin is an adipokine secreted by macrophages and inflammatory cells linked to insulin resistance and inflammation. Leptin is an adipokine regulator of appetite and obesity. Although circulating levels of both have been associated with atherosclerosis, few data have reported their relation to coronary events in the context of statin therapy. This study measured on-statin levels of both resistin and leptin through enzyme-linked immunosorbent assay in a nested case control cohort (n = 176 cases with coronary death, myocardial infarction, or unstable angina pectoris observed in follow-up matched 1:1 to 176 controls) derived from the Pravastatin or, Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 study, a randomized controlled trial of atorvastatin 80 mg/day versus pravastatin 40 mg/day in patients with a recent acute coronary syndrome. Resistin demonstrated a moderate association with high-sensitivity C-reactive protein (hsCRP; Spearman rho = 0.25, p <0.0001). On-statin resistin levels were linked to recurrent coronary events in conditional logistic regression analysis adjusted for additional risk factors including hsCRP and history of diabetes (tertile 3 vs 1 adjusted odds ratio 2.08; 95% confidence interval [CI] 1.04 to 4.19). An additive risk was noted when patients were stratified by resistin and glycated hemoglobin levels. In contrast, leptin levels were associated with obesity, diabetes, triglycerides, and hsCRP (p <0.001 for each) but demonstrated no association with recurrent coronary events (tertile 3 vs 1 adjusted odds ratio 0.72; 95% CI 0.28 to 1.83). In conclusion, on-statin resistin, but not leptin, is an independent marker of residual risk for recurrent coronary events in patients after hospitalization for an acute coronary syndrome. (C) 2015 Elsevier Inc. All rights reserved.
机译:抵抗素是由巨噬细胞和与胰岛素抵抗和炎症相关的炎性细胞分泌的脂肪因子。瘦素是食欲和肥胖的脂肪因子调节剂。尽管两者的循环水平都与动脉粥样硬化有关,但在他汀类药物治疗的背景下,很少有数据报道它们与冠状动脉事件的关系。这项研究通过巢式病例对照队列(n = 176例冠心病死亡,心肌梗塞或不稳定型心绞痛患者,在随访中与1:1配对)通过酶联免疫吸附测定法测量了抵抗素和瘦素的他汀类药物水平。 176个对照组)源自普伐他汀或阿托伐他汀在心肌梗塞中的评估和感染-血栓溶解治疗22研究,该药物是近期患有急性冠脉综合征的阿托伐他汀80毫克/天与普伐他汀40毫克/天的随机对照试验。抵抗素显示与高敏感性C反应蛋白适度相关(hsCRP; Spearman rho = 0.25,p <0.0001)。他汀类药物抵抗素水平与条件性logistic回归分析中的复发性冠脉事件相关,该条件经logistic回归分析调整为其他危险因素,包括hsCRP和糖尿病史(三分位数3比1调整后的优势比为2.08; 95%置信区间[CI]为1.04至4.19)。当患者通过抵抗素和糖化血红蛋白水平进行分层时,发现存在附加风险。相比之下,瘦素水平与肥胖症,糖尿病,甘油三酸酯和hsCRP相关(每种p <0.001),但与复发性冠心病无关(三分位数3比1调整后的优势比0.72; 95%CI 0.28至1.83)。总之,他汀类药物抵抗素而非瘦素是急性冠状动脉综合征住院后患者复发性冠脉事件残余风险的独立标志。 (C)2015 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号